The Paoli-Calmettes Institute adopts Epione, Quantum Surgical’s minimally invasive surgical robot that destroy cancerous tumors

Press releases may be edited for formatting or style | March 14, 2024 Operating Room

"This new acquisition by the Paoli-Calmettes Institute in Marseille marks a significant milestone for Quantum Surgical and is a recognition of the benefits of Epione®. We are delighted that an increasing number of patients can benefit from our minimally invasive technology, which destroys tumors while improving their comfort," states Bertin Nahum, President and Co-founder of Quantum Surgical.

About Quantum Surgical
Quantum Surgical is a French medical robotics company founded in Montpellier. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

About the Paoli-Calmettes Institute (IPC)
Founded in 1925, IPC was certified by the Haute Autorité de Santé (HAS) in 2021 with the mention of High Quality Care, the highest level of certification, and accredited as a Comprehensive Cancer Center by the OECI (Organization of European Cancer Institutes) in June 2019. With over 2,000 medical and non-medical staff members dedicated to the comprehensive management of all cancer pathologies—research, medical care, supportive care, teaching, and training—Paoli-Calmettes Institute conducted over 100,000 consultations and received nearly 12,000 new patients in 2022. Alongside IPC, CRCM is committed to sustainable improvement in patient care and quality of life through the identification and development of new treatments from innovative research programs in the field of cancer. Patient care at IPC is exclusively based on social security rates, and no additional fees are charged at the establishment. As a member of the Unicancer network, IPC has established collaborations with around twenty healthcare institutions in the region.

Back to HCB News

You Must Be Logged In To Post A Comment